Protara Therapeutics (TARA) Amortization of Deferred Charges (2020 - 2026)

Protara Therapeutics (TARA) has 7 years of Amortization of Deferred Charges data on file, last reported at $283000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 7.6% year-over-year to $283000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a 7.31% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 7.14% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $283000.0, up from $278000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for TARA reached as high as $342000.0 in Q2 2022 and fell as low as $28000.0 in Q3 2023.
• Historically, Amortization of Deferred Charges has averaged $279529.4 across 5 years, with a median of $278000.0 in 2025.
• Across the five-year window, Amortization of Deferred Charges sank 91.79% in 2023 and soared 807.14% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $342000.0 in 2022, then decreased by 11.7% to $302000.0 in 2023, then decreased by 14.24% to $259000.0 in 2024, then climbed by 7.34% to $278000.0 in 2025, then rose by 1.8% to $283000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $283000.0 in Q1 2026, $278000.0 in Q4 2025, and $273000.0 in Q3 2025.